Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response

被引：4
|
作者：
Katlama, Christine [1 ]
Assoumou, Lambert
Valantin, Marc-Antoine
Soulie, Cathia
Martinez, Esteban
Beniguel, Lydie
Bouchaud, Olivier
Raffi, Francois
Molina, Jean-Michel
Fellahi, Soraya
Peytavin, Gilles
Marcelin, Anne-Genevieve
Kolta, Sami
Capeau, Jacqueline
Gibowski, Severine
Cardon, Fanny
Reynes, Jacques
Costagliola, Dominique
机构：
[1] Hop La Pitie Salpetriere, AP HP, Serv Malad Infect & Trop, Paris, France
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2020年 / 75卷 / 12期
关键词：
D O I：
10.1093/jac/dkaa341
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：3699 / 3700
页数：2
相关论文
共 4 条
  • [1] Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study
    Katlama, Christine
    Assoumou, Lambert
    Valantin, Marc-Antoine
    Soulie, Cathia
    Martinez, Esteban
    Beniguel, Lydie
    Bouchaud, Olivier
    Raffi, Francois
    Molina, Jean-Michel
    Fellahi, Soraya
    Peytavin, Gilles
    Marcelin, Anne-Genevieve
    Kolta, Sami
    Capeau, Jacqueline
    Gibowski, Severine
    Cardon, Fanny
    Reynes, Jacques
    Costagliola, Dominique
    Bernard, Louis
    Bottero, Julie
    Bouchaud, Olivier
    Chidiac, Christian
    Duvivier, Claudine
    Goujard, Cecile
    del Mar Gutierrez, Maria
    Martinez, Esteban
    Molina, Jean-Michel
    Morlat, Philippe
    Naqvi, Alissa
    Podzamczer, Daniel
    Poizot-Martin, Isabelle
    Raffi, Francois
    Reynes, Jacques
    Salmon-Ceron, Dominique
    Simon, Anne
    Valantin, Marc-Antoine
    Weiss, Laurence
    Yazdanpanah, Yazdan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (09) : 2742 - 2751
  • [2] Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study
    Del Puente, Filippo
    Berruti, Marco
    Riccardi, Niccolo
    Di Biagio, Antonio
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) : 3698 - 3699
  • [3] Impact of the reproductive/hormonal status on weight, fat and insulin resistance in HIV-infected women switching from a PI regimen to dual raltegravir-etravirine therapy: results from the ANRS163-ETRAL trial at 48 and 96 weeks
    Assoumou, L.
    di Clemente, N.
    Fellahi, S.
    Beniguel, L.
    Bastard, J-P
    Feve, B.
    Fromentin, H.
    Katlama, C.
    Costagliola, D.
    Capeau, J.
    HIV MEDICINE, 2019, 20 : 132 - 132
  • [4] Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg ql2h) regimen
    Palich, Romain
    Allavena, Clotilde
    Peytavin, Gilles
    Soulie, Cathia
    Tubiana, Roland
    Weiss, Laurence
    Ferrer, Ana Montoya
    Duvivier, Claudine
    Bouchaud, Olivier
    Bottero, Julie
    Durand, Aurore
    Le, Minh-Patrick
    Marcelin, Anne-Genevieve
    Dudoit, Yasmine
    Assoumou, Lambert
    Katlama, Christine
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (02) : 477 - 481
1